摘要
中国是食管鳞癌的高发地。由于食管鳞癌早期症状不典型,大多数患者就诊时已为晚期,所以目前食管鳞癌治疗多以非手术治疗为主。随着肿瘤免疫学的发展,免疫治疗作为一种新的治疗方式为恶性肿瘤治疗带来了巨大的转变,其中PD-1抑制剂作为免疫治疗的重要组成部分,为包括晚期食管鳞癌在内的多种癌症患者带来了希望。目前,肿瘤免疫治疗的临床研究在国际范围内广泛开展,为指导肿瘤精准治疗提供了更多理论依据。本文就目前国内外相关研究,就PD-1抑制剂对晚期食管鳞癌的疗效及治疗安全性进行综述。
China is a high-risk area for esophageal squamous cell carcinoma.Due to the atypical early symptoms of esophageal squamous cell carcinoma and the fact that most patients are already in the advanced stage of treatment,non-surgical treatment is currently the main treatment for esophageal squamous cell carcinoma.With the development of tumor immunology,immunotherapy,as a new treatment method,has brought great changes to the treatment of malignant tumors.PD-1 inhibitors,as an important part of immunotherapy,have brought new hope to patients with multiple cancers,including advanced esophageal squamous cell carcinoma.At present,clinical researches on tumor immunotherapy are widely carried out internationally,providing more theoretical basis for guiding precise tumor treatment.This article reviews the research progress on the efficacy and safety of PD-1 inhibitors in advanced esophageal squamous cell carcinoma.
作者
史雅瑄
刘彩霞
SHI Yaxuan;LIU Caixia(Inner Mongolia Medical University,Hohhot 010059,China;Department of Medical Oncology,The Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,China)
出处
《内蒙古医科大学学报》
2023年第1期95-100,共6页
Journal of Inner Mongolia Medical University
基金
内蒙古自治区科技计划项目(2020GG0171)
内蒙古医科大学基金项目(YKD2021MS030)。
关键词
食管鳞癌
免疫治疗
PD-1抑制剂
Esophageal squamous cell carcinoma
Immunotherapy
PD-1 inhibitors
